secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001628280-26-001743
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M
--------------------------------------------------------------------------------

- Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.
- Revenue growth exceeded prior guidance of 50% annual growth for 2025.
- Initial 2026 revenue guidance set at $60M to $62M.
- Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/0001628280-26-001743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/tlsi-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer